Immunic Stock Gets Reduced EPS Estimate from HC Wainwright

Immunic, Inc. (NASDAQ:IMUX – Free Report) – HC Wainwright lowered their FY2030 earnings per share (EPS) estimates for Immunic in a research note issued on Monday, November 16th. HC Wainwright analyst M. Caufield now anticipates that the company will earn $0.33 per share for the year, down from their prior forecast of $0.40. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.79) per share.

Immunic (NASDAQ:IMUX – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20).

IMUX has been the subject of a number of other reports. Ladenburg Thalmann & Co. Inc. upgraded Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Roth Capital reiterated a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Immunic in a report on Thursday, September 10th. Cantor Fitzgerald began coverage on shares of Immunic in a report on Friday, October 23rd. They issued an “overweight” rating for the company. Finally, Wall Street Zen lowered shares of Immunic from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 14th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immunic currently has a consensus rating of “Moderate Buy” and an average price target of $32.71.

View Our Latest Stock Report on Immunic

Immunic Trading Up 2.6%

IMUX opened at $7.52 on Tuesday. The firm has a market cap of $119.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.48. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43. The stock has a fifty day moving average price of $8.38 and a 200-day moving average price of $11.54.

Hedge Funds Weigh In On Immunic

Institutional investors and hedge funds have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Immunic during the first quarter worth $27,000. ADAR1 Capital Management LLC acquired a new stake in shares of Immunic in the 1st quarter worth $33,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Immunic by 21.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock worth $69,000 after purchasing an additional 1,400 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after purchasing an additional 143,689 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in Immunic by 28.0% during the 3rd quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock worth $165,000 after buying an additional 3,870 shares during the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic News Roundup

These are some of the IMUX news items that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $22 price target, while raising its Q4 2026 and FY2027 EPS estimates to smaller expected losses. That offers some support, although the company is still forecast to report losses. MarketBeat analyst estimates
  • Neutral Sentiment: A December multiple-sclerosis readout is approaching and could be a significant catalyst for IMUX. The article frames the data as a potential driver of a rally, but the outcome is uncertain and could also disappoint investors. Immunic nears multiple sclerosis readout
  • Negative Sentiment: Forecast revisions were not uniformly positive: Brookline Capital Markets lowered its Q4 and FY2026 estimates to larger losses, and HC Wainwright reduced estimates for several later years. Wall Street Zen also cut its rating on Immunic to “Strong Sell,” adding to cautious sentiment. Immunic cut to Strong Sell at Wall Street Zen

Immunic Company Profile

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

See Also

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.